Can Fite BioPharma Ltd (CANF)

[Spideyboy]

Hi Midas,

This I don't believe is anything to be disappointed about. And even I take this in a positive light.

Psoriasis has different levels of severity. Feel free to watch the whole video as it is short, but can skip to minute 8:30.

The current Comfort Phase III psoriasis trial is in moderate to severe plaque psoriasis patients. These are patients that will have a manifestation in multiple parts of the body and will be in a more severe form of manifestation. https://clinicaltrials.gov/ct2/show/NCT03168256?term=can+fite&draw=3&rank=14 "This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with moderate to severe plaque psoriasis will relieve signs and symptoms of the disease. CF101 effect will be in comparison to apremilast in this study population"

However psoriasis also exists in more mild forms which may be limited to just one part of the body, for example a hand, or a foot, or a part of one arm, while only affecting a limited area such a mild form will also have more mild severity in manifestation.

Therefore in the more mild/limited psoriasis situation, topical treatments are currently the go to treatment modality. As the situation progresses across the body and/or increases in severity it is no longer practical to spread a topical treatment across the whole body every day nor will the efficacy be probably as effective to treat the more severe situation. Thus a systemic and preferably oral anti-psoriasis treatment modality is more practical and effective.

Thus why Can-Fite states that this potential topical formulation would be complimentary to the current systemic oral modality in the current Phase III trial.

I in fact take this as in general as positive news, as while the level of efficacy is not specifically mentioned, it does indicate that via a new application modality, topical to the skin, the drug appears to exert its anti-psoriasis effect. Thus apparent consistent anti-psoriasis efficacy appear to be further demonstrated and hopefully bodes will for the upcoming psoriasis Phase III data.

Additionally, given the market research report mentioned in the PR states the below:

"Category-wise Insights
Which Type of Psoriasis Drug is Driving Market Growth?

“Topical Psoriasis Treatment Hugely Popular”

Topical treatment projects lucrative growth at a CAGR of 6.3% through 2031, with a market share of 41% in 2021."
https://www.persistencemarketresearch.com/market-research/psoriasis-drugs-market.asp

Then it would be great is Can-Fite could have products that could treat the whole spectrum with a new effective and safe alternative to what is already out there.

All the best,
Spidey